Literature DB >> 32588971

A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment.

Jennifer H Lingler1,2, Susan M Sereika1, Meryl A Butters3, Ann D Cohen2,3, William E Klunk2,3,4, Melissa L Knox1, Eric McDade5, Neelesh K Nadkarni2,4,6, J Scott Roberts7, Lisa K Tamres1, Oscar L Lopez2,3,4.   

Abstract

INTRODUCTION: Recent studies suggest that Alzheimer's disease (AD) biomarker disclosure has no discernable psychological impact on cognitively healthy persons. Far less is known about how such results affect symptomatic individuals and their caregivers.
METHODS: Randomized controlled trial of 82 mild cognitive impairment (MCI) patient and caregiver dyads (total n = 164) to determine the effect of receiving amyloid positron emission tomography results on understanding of, and perceived efficacy to cope with, MCI over 52 weeks of follow-up.
RESULTS: Gains in the primary outcomes were not consistently observed. Amyloid negative patients reported greater perceived ambiguity regarding MCI at follow-up, while moderate and sustained emotional distress was observed in patients, and to a lesser extent, caregivers, of those who were amyloid positive. There was no corresponding increase in depressive symptoms. DISCUSSION: These findings point to the possibility that both MCI patients and caregivers may need emotional support after the disclosure of amyloid scan results.
© 2020 the Alzheimer's Association.

Entities:  

Keywords:  amyloid positron emission tomography; biomarker disclosure; caregiving; ethics; mild cognitive impairment

Year:  2020        PMID: 32588971      PMCID: PMC7541680          DOI: 10.1002/alz.12129

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  13 in total

1.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  A new scale measuring psychologic impact of genetic susceptibility testing for Alzheimer disease.

Authors:  Winston W Chung; Clara A Chen; L Adrienne Cupples; J Scott Roberts; Susan C Hiraki; Anil K Nair; Robert C Green; Robert A Stern
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jan-Mar       Impact factor: 2.703

3.  Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging.

Authors:  Keith A Johnson; Satoshi Minoshima; Nicolaas I Bohnen; Kevin J Donohoe; Norman L Foster; Peter Herscovitch; Jason H Karlawish; Christopher C Rowe; Saima Hedrick; Virginia Pappas; Maria C Carrillo; Dean M Hartley
Journal:  Alzheimers Dement       Date:  2013-07       Impact factor: 21.566

4.  A validity and reliability study of the coping self-efficacy scale.

Authors:  Margaret A Chesney; Torsten B Neilands; Donald B Chambers; Jonelle M Taylor; Susan Folkman
Journal:  Br J Health Psychol       Date:  2006-09

5.  Disclosure of amyloid imaging results to research participants: has the time come?

Authors:  Jennifer H Lingler; William E Klunk
Journal:  Alzheimers Dement       Date:  2013-02-13       Impact factor: 21.566

6.  Disclosure of amyloid PET scan results: A systematic review.

Authors:  Hyejin Kim; Jennifer H Lingler
Journal:  Prog Mol Biol Transl Sci       Date:  2019-06-13       Impact factor: 3.622

7.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

Authors:  Christopher M Clark; Michael J Pontecorvo; Thomas G Beach; Barry J Bedell; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Eric M Reiman; Marwan N Sabbagh; Carl H Sadowsky; Julie A Schneider; Anupa Arora; Alan P Carpenter; Matthew L Flitter; Abhinay D Joshi; Michael J Krautkramer; Ming Lu; Mark A Mintun; Daniel M Skovronsky
Journal:  Lancet Neurol       Date:  2012-06-28       Impact factor: 44.182

8.  Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.

Authors:  Jennifer H Lingler; Meryl A Butters; Amanda L Gentry; Lu Hu; Amanda E Hunsaker; William E Klunk; Meghan K Mattos; Lisa S Parker; J Scott Roberts; Richard Schulz
Journal:  J Alzheimers Dis       Date:  2016-03-08       Impact factor: 4.472

9.  Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure.

Authors:  Jennifer H Lingler; J Scott Roberts; Hyejin Kim; Jonna L Morris; Lu Hu; Meghan Mattos; Eric McDade; Oscar L Lopez
Journal:  Alzheimers Dement (Amst)       Date:  2018-05-30

Review 10.  Research Use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid-β Results Disclosure.

Authors:  Meghan K Mattos; Susan M Sereika; Scott R Beach; Hyejin Kim; William E Klunk; Melissa Knox; Neelesh K Nadkarni; Lisa S Parker; J Scott Roberts; Richard Schulz; Lisa Tamres; Jennifer H Lingler
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

View more
  4 in total

1.  Do Perceptions of Cognitive Changes Matter in Self-Management Behaviors Among Persons With Mild Cognitive Impairment?

Authors:  Hyejin Kim; Susan M Sereika; Steven M Albert; Catherine M Bender; Jennifer H Lingler
Journal:  Gerontologist       Date:  2022-04-20

2.  Dyadic Enrollment in a Phase 3 Mild Cognitive Impairment Clinical Trial.

Authors:  Navneet R Hakhu; Daniel L Gillen; Joshua D Grill
Journal:  Alzheimer Dis Assoc Disord       Date:  2022-04-29       Impact factor: 2.357

Review 3.  Ethical Considerations in Communicating Alzheimer's Disease Neuroimaging Biomarker Test Results to Symptomatic Individuals.

Authors:  Daniel A Wilkenfeld; Staci L Orbell; Jennifer H Lingler
Journal:  Neurotherapeutics       Date:  2021-04-15       Impact factor: 7.620

4.  Disclosure of individual research results at federally funded Alzheimer's Disease Research Centers.

Authors:  J Scott Roberts; Rebecca Ferber; Deborah Blacker; Malia Rumbaugh; Joshua D Grill
Journal:  Alzheimers Dement (N Y)       Date:  2021-10-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.